Beyond Antihyperglycemic and Antihypertensive Agents for Diabetic Kidney Disease
Monday, June 26, at 3:15 p.m. PT
Room 28
San Diego Convention Center
(Livestream Available)
Presentation: Are We Following the Guidelines and Using the Newer Therapies to Protect Against Diabetic Kidney Disease?
Christine P. Limonte, MD
Assistant Professor, Division of Nephrology,
University of Washington
What is your presentation about?
I will be discussing patterns of use of novel kidney protective agents (SGLT2i, GLP1-RA, steroidal MRA) and barriers in their implementation.
What makes this topic important in 2023?
Over the last several years, a number of novel therapeutic agents have emerged which have proven to be tremendously effective in slowing diabetic kidney disease progression. Understanding how these medications are presently being used and how implementation can be improved is important for advancing diabetic kidney disease care.
How did you become involved with this area of diabetes research or care?
Diabetic kidney disease affects a large proportion of people with diabetes and is associated with significant morbidity and mortality. I am passionate about research that focuses on identifying people at risk for diabetic kidney disease and optimizing diabetic kidney disease treatment strategies.
How do you think your presentation will impact diabetes research or care?
I hope my presentation increases awareness of the beneficial impacts these novel therapeutic agents have on diabetic kidney disease and emboldens providers to promote their use.
What are you most looking forward to at the 83rd Scientific Sessions?
I look forward to learning from my colleagues who are passionate about improving the lives of people with diabetes.
Presentation: Future Therapies Targeting Mitochondrial Dysfunction and Oxidative Stress to Mitigate Diabetic Kidney Disease (Intracellular NAD+, JAK-STAT, TGFbeta)
Ashish Verma, MBBS
Assistant Professor of Medicine,
Boston University Chobanian & Avedisian School of Medicine
What is your presentation about?
My presentation is on future therapies targeting mitochondrial dysfunction and oxidative stress to mitigate diabetic kidney disease. Recently, system biology methods have allowed the elucidation of signaling pathways and networks involved in the progression of DKD that were not well appreciated previously. I will talk about therapies that target different signaling pathways, like JAK-STAT, TGF-beta, and intracellular NAD+ levels.
What makes this topic important in 2023?
Globally, diabetes is the leading cause of chronic kidney disease and end-stage renal disease, which are major risk factors for cardiovascular disease and death. Recently there has been the emergence of therapies like SGLT2 inhibitors and non-steroidal MR antagonists to prevent the progression of DKD and cardiovascular adverse events in patients with proteinuric DKD. We still have a long way to go to have therapies for patients with DKD phenotypes without proteinuria and the more therapies we will have for DKD, the less risk patients will have for end-stage kidney disease.
How did you become involved with this area of diabetes research or care?
I am very interested in understanding the pathogenesis and progression of diabetic kidney disease. I am currently working on identifying the predictors of DKD phenotypes and the differential risk among these phenotypes of adverse cardiovascular events and end-stage kidney disease. I am also a co-investigator on a phase 2 randomized control trial named NAD+ supplementation in diabetic kidney disease.
How do you think your presentation will impact diabetes research or care?
This presentation will educate audiences on different targets specifically pertaining to mitochondrial dysfunction and oxidative stress that can pave the way to probable therapies in the future to halt diabetic kidney disease progression.
What are you most looking forward to at the 83rd Scientific Sessions?
I am very excited to be a presenter at the 83rd Scientific Sessions. I am looking forward to learning about diabetic kidney disease and other diabetic complications through different presentations. I am also looking forward to networking with other researchers with common interests like me in diabetic kidney disease.